NUVB Relative Valuation
NUVB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NUVB is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for NUVB's competitors is 17567.53, providing a benchmark for relative valuation. Nuvation Bio Inc Corp (NUVB) exhibits a P/S ratio of 25.46, which is -99.86% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
ASIX
AdvanSix Inc
24.480
USD
+0.33%
BELFB
Bel Fuse Inc
74.960
USD
-0.74%
DEC
Diversified Energy Company PLC
14.010
USD
+1.60%
WLKP
Westlake Chemical Partners LP
22.520
USD
-0.92%
OEC
Orion SA
11.500
USD
+3.42%
PRAA
PRA Group Inc
14.840
USD
+0.20%
PAHC
Phibro Animal Health Corp
24.090
USD
-0.17%
PPTA
Perpetua Resources Corp
13.720
USD
+7.44%
FUFU
BitFuFu Inc
3.790
USD
-5.01%
HFWA
Heritage Financial Corp
24.010
USD
+0.54%
FAQ
Is Nuvation Bio Inc (NUVB) currently overvalued or undervalued?
Nuvation Bio Inc (NUVB) is now in the Fair zone, suggesting that its current forward PS ratio of 25.46 is considered Fairly compared with the five-year average of 46.24. The fair price of Nuvation Bio Inc (NUVB) is between to according to relative valuation methord.
What is Nuvation Bio Inc (NUVB) fair value?
How does NUVB's valuation metrics compare to the industry average?
What is the current P/B ratio for Nuvation Bio Inc (NUVB) as of May 21 2025?
What is the current FCF Yield for Nuvation Bio Inc (NUVB) as of May 21 2025?
What is the current Forward P/E ratio for Nuvation Bio Inc (NUVB) as of May 21 2025?